Journal of Clinical Oncology
Articles in this Issue
Accelerated aging among long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
10064 Background: Cross-sectional studies have suggested childhood cancer survivors demonstrate a pattern of functional limitations and morbidity consiste...
Palbociclib plus endocrine therapy or GnRH analogs versus capecitabine or placebo for HR+/HER2- metastatic breast cancer: A systematic review and meta-analysis.
e13018 Background: Breast cancer, particularly the HR+/HER2- subtype, remains a major global health concern. Palbociclib, a CDK4/6 inhibitor, has demonstr...
Tumor-informed liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: The LIQUID study.
4067 Background: Gastroesophageal cancers (GEC) shows high recurrence rates after curative surgery with or without perioperative/adjuvant chemotherapy. Pa...
Epigenetic and transcriptional consequences of MTAP-loss in lung adenocarcinoma.
8624 Background: Lung adenocarcinoma (LUAD), the most common lung cancer subtype, has poor survival rates and limited treatment options. Among its molecul...
Transarterial chemoembolization plus donafenib with or without anti-PD-1 antibodies for unresectable hepatocellular carcinoma: A retrospective study.
e16245 Background: Transarterial chemoembolization (TACE) can effectively reduce tumor burden by delivering chemotherapy drugs directly to the tumor while...
A natural language processing (NLP) approach for optical character recognition (OCR)-resilient extraction, correction, and structuring of karyotype data in oncology clinical notes.
e13644 Background: Cytogenetics drives precision oncology by uncovering genetic abnormalities that contribute to cancers. Karyotypes, essential for cytoge...
Efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced differentiated thyroid cancer (DTC): A multicenter, single-arm, phase II study.
6096 Background: Neoadjuvant therapy is often necessary for patients with locally advanced inoperable or locally recurrent thyroid cancer without chance o...
Mortality trends and disparities affecting pharyngeal cancer in the US: A 21-year retrospective analysis of CDC WONDER database.
e18144 Background: Pharyngeal cancer, or throat cancer, includes nasopharyngeal, oropharyngeal, and hypopharyngeal cancers, with the most common histologi...
Epidemiology, racial-socioeconomic disparities, and outcomes of T-cell prolymphocytic leukemia: A comprehensive analysis of the SEER database (2000-2021).
e18541 Background: T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive mature T-cell neoplasm. There is limited population level data on T-PLL...
Efficacy of nanoliposomal irinotecan in metastatic pancreatic ductal adenocarcinoma: A meta-analysis of NAPOLI randomized clinical trials.
e16429 Background: Nanoliposomal irinotecan (Nal-IRI) is a DNA topoisomerase I inhibitor that recently showed promising results for the treatment of metas...
Patient and caregiver treatment preferences for ALK+ non-small cell lung cancer in the United States.
8617 Background: Treatment options for non-small cell lung cancer (NSCLC) with ALK rearrangement (ALK+) have distinct benefits and risks. As patients ofte...
Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.
5529 Background: ZG005, a PD-1 and TIGIT dual-specific antibody, is a promising immunotherapy for tumors. By blocking both pathways, it can synergisticall...
Longitudinal assessment from liquid biopsy of mutations in CD20: A pilot study using a PETE enrichment strategy.
7042 Background: In recent years, bispecific T cell Engagers (BsTCE) targeting CD3 and CD20 have emerged as a potent new class of therapeutics for NHL; ho...
RNA-based fusion NGS panel testing for the improved classification of soft tissue sarcomas: A retrospective analysis.
11541 Background: Accurate diagnosis of soft tissue sarcomas (STS) is critical for effective clinical management. The integration of genetic data enables...
Impact of genomic alterations on outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Lu-177 radioligand therapy (RLT).
e17099 Background: The genomic landscape of mCRPC has been shown to effect response to certain therapies (e.g. PARP inhibitors); however, the impact of mu...
Public awareness, adherence, and cost-effectiveness of cancer screening programs: Insights from national surveys (2015-2023).
e13539 Background: Cancer screening programs are crucial for early detection and improved outcomes, yet disparities exist in adherence, awareness, and cos...
γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION.
6507 Background: AML impairs immunosurveillance bypassing target recognition and subsequent cytotoxic T cell responses. Immunomodulatory and cytotoxic eff...
The landscape and effectiveness of patient retention strategies in cancer clinical trials.
e23005 Background: Withdrawal without a defined reason (WWDR) can introduce unintended bias and reduce generalizability in therapeutic cancer clinical tri...
A nation's uneven battle: Trends and regional disparities in cancer mortality.
e22563 Background: Cancer and diabetes represent leading causes of mortality in the United States, with considerable disparities in rates across demograph...
Comparative outcomes of abiraterone and androgen receptor inhibitors (ARPIs) in metastatic castration-sensitive prostate cancer (mCSPC): A real-world analysis from the TriNetX database.
e17119 Background: Abiraterone and ARPIs, including enzalutamide and apalutamide, in combination with androgen deprivation therapy (ADT), are standard tre...
Prevalence of sexual dysfunction among men with cancer before the initiation of systemic treatment.
12049 Background: Sexual health significantly impacts the quality of life, yet its relationship with systemic cancer treatments in men remains underexplor...
Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.
2625 Background: Immune checkpoint inhibitors (ICIs) have become a standard treatment, yet no universal biomarker consistently predicts prolonged survival...
The feasibility of personalized and tumor-informed ctDNA assay for early recurrence detection in post-liver transplantation patients with hepatocellular carcinoma.
e16283 Background: Hepatocellular carcinoma (HCC) has a high likelihood of relapse following standard-of-care (SOC) resection or liver transplantation (LT...
Infectious events in patients treated for malignancies with T-cell engagers immunotherapies, a cohort study from the French REISAMIC registry.
e24081 Background: Infectious complications were recently reported in patients (pts) receiving T-cell engager (TCE) therapy and require further investigat...
Reproducibility of the correlation between race and outcomes associated with treatment of HER2+ breast cancer across databases.
e13769 Background: HER2-positive (HER2+) breast cancer (BrCa) is an aggressive subtype, accounting for 20–30% of all BrCa cases. Trastuzumab, a monoclonal...